Press

PharmAla Biotech to Supply University of Sydney Clinical Trial with LaNeo™ MDMA

Aug 31 • 2 min read

PharmAla Biotech (CSE: MDMA) is proud to have been selected as the MDMA manufacturing partner for the University of Sydney’s upcoming Phase 2 Clinical Trial. Founded in 1850, The University of Sydney is one of the top universities in Australia There is a high rate of comorbidity between alcohol use disorders and Post Traumatic Stress Disorder which is associated with…

PSYC Completes and Publishes 2021 Audited Financials; Will Begin Audit of Q1 & Q2 2022

Aug 31 • 4 min read

PSYC Corporation (OTCPink: PSYC), a media leader focused on the emerging psychedelic sector through its flagship platform, Psychedelic Spotlight, completed and published its 2021 Audited Financials. The accomplishment comes after PSYC completed its 2020 Audited Financials in March, representing an important milestone as it works towards becoming a fully current SEC reporting company and up listing to the OTCQB. Following the…

Mindset Pharma Further Expands its IP Portfolio with Three Additional Non-Tryptamine Families of Next-Generation Psychedelic Compounds

Aug 31 • 3 min read

Mindset Pharma, Inc (CSE: MSET | FSE: 9DF | OTCQB: MSSTF), a drug discovery and development company focused on creating novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced that through its discovery work, it has identified three additional families of highly novel, non-tryptamine, next-generation…

Bright Minds Biosciences Announces Closing of $4 Million Unit Offering

Aug 31 • 2 min read

Bright Minds Biosciences Inc. (CSE:DRUG | NASDAQ:DRUG) is pleased to announce that it has closed its previously announced overnight marketed offering of 2,858,000 units of the Company at a price of $1.40 per Unit for gross proceeds of approximately $4 million. Each Unit is comprised of one common share in the capital of the Company…

Wellbeing’ CEO Joins Benzinga’s Psychedelic Advisory Board

Aug 30 • 3 min read

Wellbeing Digital Sciences Inc. (NEO: MEDI | OTC: KONEF | FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, today announce the appointment of Najla Guthrie to the Benzinga Psychedelic Advisory Council. The Benzinga Psychedelics Advisory Council is a…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441